The second therapy involves reactivating the production of foetal haemoglobin as a substitute for the deficient adult haemoglobin in beta-thalassemia and sickle cell anaemia. Dr Mian and his team will work on gene-silencing, using the same gene-editing tool and approach, suppressing the BCL11A gene that stops foetal haemoglobin from being produced.
For this project, the research team at CRM is collaborating with researchers at:
- University of California, San Francisco
- Norwegian University of Science and Technology
- Cardiff University in the UK
Team Members
Dr Fawad Ur Rahman, Postdoctoral Fellow
Dr Muhammad Jameel, Postdoctoral Fellow
Fizza Iftikhar, Postdoctoral Fellow
Dr Irfan Hussain, Postdoctoral Fellow
Syeda Roohina Ali, Postdoctoral Fellow
Zahra Sajid, Research Associate
Kainaat Mumtaz, Research Associate
Rida e Maria Qazi, Research Associate